✦ LIBER ✦

Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma

✍ Scribed by A.M.M. Eggermont

Book ID: 117664222
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 72 KB
Volume: 34
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)10160-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

521 THE ROLE OF ADJUVANT TREATMENT STRAT

521 THE ROLE OF ADJUVANT TREATMENT STRATEGIES AFTER SURGERY FOR HIGH-RISK LOCALIZED PROSTATE CANCER

✍ M. Spahn; S. Joniau; P. Gontero; B. Tombal; J. Walz; C.Y. Hsu; G. Marchioro; K. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 510 KB

Systemic adjuvant treatment of high-risk

Systemic adjuvant treatment of high-risk melanoma: the role of interferon Alfa-2b and other immunotherapies

✍ J.M Kirkwood 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Does adjuvant interferon-α for high-risk

Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

✍ Keith Wheatley; Natalie Ives; Barry Hancock; Martin Gore; Alexander Eggermont; S 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Acute toxicity of curative radiotherapy

Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991

✍ O. Matzinger; F. Duclos; A. van den Bergh; C. Carrie; S. Villà; P. Kitsios; P. P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 531 KB

The benefits of adjuvant radiation thera

The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma

✍ Shefali Agrawal; John M. Kane III; Beverly A. Guadagnolo; William G. Kraybill; M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

Immunomodulatory effects of high-dose an

Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma : The E2690 laboratory corollary of Intergroup Adjuvant Trial E1690

✍ John M. Kirkwood; Thomas Richards; Hassane M. Zarour; Jeffrey Sosman; Marc Ernst 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Background: The clinical antitumor activity of recombinant interferon alpha2b (ifnalpha2b) has been well documented in patients with advanced and high-risk melanoma; however, its mechanism of action remains conjectural. trial e2690 evaluated the immunomodulatory effects of ifnalpha2b in vivo dur